Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
复制标题
淋巴瘤患者在接受抗 CD2O 抗体治疗后的前 12 个月内，对 BNT162b2 疫苗的体液血清学反应消失。
作者：
R. Gurion;U. Rozovski;G. Itchaki;A. Gafter;C. Leibovitch;P. Raanani;H. Ben‐Zvi;M. Szwarcwort;M. Taylor;E. Dann;Nurit Horesh;T. Inbar;I. Tzoran;N. Lavi;R. Fineman;S. Ringelstein;N. Horowitz
淋巴瘤患者，尤其是接受抗 CD20 单克隆抗体 (MoAb) 治疗的患者，患有与 COVID-19 相关的高发病率和死亡率。本研究的目的是评估淋巴瘤患者在两次注射 BNT162b2 辉瑞疫苗后产生足够体液反应的能力，并确定影响反应的因素。在接种第二剂疫苗 4±2 周后，使用 SARS-CoV-2 IgG II Quant (Abbott©) 测定法对从淋巴瘤患者抽取的血液样本中测量抗体滴度。阳性反应的截止值设定为 50AU/ml。在参与这项横断面研究的 162 名患者中，51% 的患者观察到阳性血清学反应。在多变量分析中，区间为。
Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies (MoAb), suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral response after two injections of BNT162b2 Pfizer vaccine and to identify factors impacting the response. Antibody titers were measured with the SARS-CoV-2 IgG II Quant (Abbott©) assay in blood samples drawn from lymphoma patients 4±2 weeks after the 2nd vaccine dose. The cutoff for a positive response was set at 50AU/ml. Positive serological responses were observed in 51% of the 162 patients enrolled in this cross-sectional study. In a multivariate analysis, an interval of.
影响因子：
82.9
作者：
Robilotti EV;Babady NE;Mead PA;Rolling T;Perez-Johnston R;Bernardes M;Bogler Y;Caldararo M;Figueroa CJ;Glickman MS;Joanow A;Kaltsas A;Lee YJ;Lucca A;Mariano A;Morjaria S;Nawar T;Papanicolaou GA;Predmore J;Redelman-Sidi G;Schmidt E;Seo SK;Sepkowitz K;Shah MK;Wolchok JD;Hohl TM;Taur Y;Kamboj M
通讯作者：
Kamboj M
影响因子：
15.9
作者：
Shah, Gunjan L.;DeWolf, Susan;Perales, Miguel-Angel
通讯作者：
Perales, Miguel-Angel